GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascelia Pharma AB (OSTO:ACE) » Definitions » Asset Turnover

Ascelia Pharma AB (OSTO:ACE) Asset Turnover : 0.00 (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Ascelia Pharma AB Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Ascelia Pharma AB's Revenue for the three months ended in Dec. 2024 was kr0.00 Mil. Ascelia Pharma AB's Total Assets for the quarter that ended in Dec. 2024 was kr151.16 Mil. Therefore, Ascelia Pharma AB's Asset Turnover for the quarter that ended in Dec. 2024 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Ascelia Pharma AB's annualized ROE % for the quarter that ended in Dec. 2024 was -121.51%. It is also linked to ROA % through Du Pont Formula. Ascelia Pharma AB's annualized ROA % for the quarter that ended in Dec. 2024 was -74.97%.


Ascelia Pharma AB Asset Turnover Historical Data

The historical data trend for Ascelia Pharma AB's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascelia Pharma AB Asset Turnover Chart

Ascelia Pharma AB Annual Data
Trend Jun17 Jun18 Jun19 Dec20 Dec21 Dec22 Dec23 Dec24
Asset Turnover
Get a 7-Day Free Trial - - - - -

Ascelia Pharma AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Ascelia Pharma AB's Asset Turnover

For the Biotechnology subindustry, Ascelia Pharma AB's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascelia Pharma AB's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascelia Pharma AB's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Ascelia Pharma AB's Asset Turnover falls into.



Ascelia Pharma AB Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Ascelia Pharma AB's Asset Turnover for the fiscal year that ended in Dec. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2024 )/( (Total Assets (A: Dec. 2023 )+Total Assets (A: Dec. 2024 ))/ count )
=0/( (87.072+140.92)/ 2 )
=0/113.996
=0.00

Ascelia Pharma AB's Asset Turnover for the quarter that ended in Dec. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2024 )/( (Total Assets (Q: Sep. 2024 )+Total Assets (Q: Dec. 2024 ))/ count )
=0/( (161.409+140.92)/ 2 )
=0/151.1645
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Ascelia Pharma AB  (OSTO:ACE) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Ascelia Pharma AB's annulized ROE % for the quarter that ended in Dec. 2024 is

ROE %**(Q: Dec. 2024 )
=Net Income/Total Stockholders Equity
=-113.328/93.263
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-113.328 / 0)*(0 / 151.1645)*(151.1645/ 93.263)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*1.6208
=ROA %*Equity Multiplier
=-74.97 %*1.6208
=-121.51 %

Note: The Net Income data used here is four times the quarterly (Dec. 2024) net income data. The Revenue data used here is four times the quarterly (Dec. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Ascelia Pharma AB's annulized ROA % for the quarter that ended in Dec. 2024 is

ROA %(Q: Dec. 2024 )
=Net Income/Total Assets
=-113.328/151.1645
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-113.328 / 0)*(0 / 151.1645)
=Net Margin %*Asset Turnover
= %*0
=-74.97 %

Note: The Net Income data used here is four times the quarterly (Dec. 2024) net income data. The Revenue data used here is four times the quarterly (Dec. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Ascelia Pharma AB Asset Turnover Related Terms

Thank you for viewing the detailed overview of Ascelia Pharma AB's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Ascelia Pharma AB Business Description

Traded in Other Exchanges
Address
Hyllie Boulevard 34, Malmo, SWE, SE-215 32
Ascelia Pharma AB is an oncology-dedicated drug development company located in Malmo Sweden focused on orphan oncology It develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway The company has two drug candidates Orviglance and Oncoral in clinical development.

Ascelia Pharma AB Headlines

No Headlines